Boundless Bio (BOLD) Non-Current Assets (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Non-Current Assets of $46.4 million for Q1 2026, down 8.89% year-over-year from $50.9 million in Q1 2025, and down 2.31% quarter-over-quarter from $47.4 million in Q4 2025.
Boundless Bio (BOLD) Non-Current Assets (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Non-Current Assets for 4 consecutive years, with $46.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 8.89% year-over-year to $46.4 million; the TTM figure through Mar 2026 stood at $192.1 million (up 70.61% YoY), while the FY2025 annual figure was $47.4 million, down 8.79% from the prior year.
- Non-Current Assets eased to $46.4 million in Q1 2026 per BOLD's latest filing, from $47.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $52.0 million in Q4 2024 and bottomed at $4.6 million in Q3 2024.
- Historically, Non-Current Assets has averaged $31.5 million across 4 years, with a median of $46.9 million in 2025.
- Annual changes were most pronounced in 2025 — Non-Current Assets soared 945.76% — and 2026, when it slipped 8.89%.
- Boundless Bio's Non-Current Assets stood at $5.7 million in 2023, then surged by 814.22% to $52.0 million in 2024, then declined by 8.79% to $47.4 million in 2025, then slipped by 2.31% to $46.4 million in 2026.
- Business Quant data shows BOLD's Non-Current Assets at $46.4 million in Q1 2026, $47.4 million in Q4 2025, and $48.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Boundless Bio | 66.90 Mn | 66.90 Mn | - | 97,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97,000.00 |
| Mar 31, 2026 | 46.35 Mn |
| Dec 31, 2025 | 47.45 Mn |
| Sep 30, 2025 | 48.57 Mn |
| Jun 30, 2025 | 49.76 Mn |
| Mar 31, 2025 | 50.88 Mn |
| Dec 31, 2024 | 52.02 Mn |
| Sep 30, 2024 | 4.64 Mn |
| Jun 30, 2024 | 5.07 Mn |
| Mar 31, 2024 | 4.92 Mn |
| Dec 31, 2023 | 5.69 Mn |